We examined the hypothesis that the positive inotropic effect of angiotensin I (Ang I) may be retained in the presence of angiotensin converting enzyme inhibitors so that it may have a direct beneficial effect on the heart. Accordingly, isolated perfused hearts (Langendorff preparation) of 300-day-old cardiomyopathic hamsters (a model of spontaneous cardiomyopathy) and age-matched normal hamsters (controls) were infused with Ang I in the presence of captopril; propranolol was added to the perfusing medium to block catecholamine-mediated effects of angiotensins on the heart. Left ventricular developed pressure and the rate of increase in left ventricular developed pressure increased significantly (p<0.01) in both the cardiomyopathic and the normal hamster heart despite concomitant reduction in myocardial flow rate favoring a direct inotropic effect of Ang I in both normal and myopathic hearts; these changes were significantly higher by almost threefold in the cardiomyopathic than in the normal hamsters (p<0.01) and were blocked by the angiotensin II (Ang II) antagonist [Sarl,Thr8] there is yet another aspect to be considered: a direct cardiac positive inotropic effect of angiotensin I (Ang I), which is accumulated during inhibition of the Ang
mechanism by which ACE inhibitors improve cardiac performance is still not well understood. The cardiac unloading effect of ACE inhibitors is shared by other vasodilators. Reduction in aldosterone release during treatment with ACE inhibitors was thought to mediate the lack of development of tolerance during therapy, but its direct relation to the long-term improvement of congestive heart failure has not been proven. Chronic reduction of angiotensin II (Ang II) concentration improves renal blood flow by reducing efferent glomerular arteriolar constriction12 and improves renal tubular excretion of sodium.13 In addition to these mechanisms, and in view of the reported positive inotropic effects of angiotensin peptides in isolated normal cat papillary muscle, '4 there is yet another aspect to be considered: a direct cardiac positive inotropic effect of angiotensin I (Ang I), which is accumulated during inhibition of the Ang I converting enzyme. However, this putative inotropic effect of Ang I was confounded by other reports showing a diminished Ang I inotropic action in the presence of an ACE inhibitor15 and a total loss of inotropic effect of Ang I in the presence of Ang II antagonists. These latter findings suggest that cardiac Ang I effects may be mediated in part via Ang II and Ang II receptors. We designed this study to 1) evaluate the mechanism of inotropic effects of Ang I during blockade of the known ACE and 2) determine if a differential inotropic effect of Ang I exists between cardiomyopathic hamster (CMH) and normal hamster (NH) hearts to explain a unique benefit in the setting of severe heart failure. We hypothesized that the positive inotropic effect of Ang I may be retained in the presence of captopril, so that it may produce a beneficial effect on the diseased myocardium. The Syrian hamster, which provides a model of spontaneous heart failure,16 was used to study the effects of Ang I on the compensated and failing heart. The isolated perfused Langendorff method17 was chosen to allow examination of the effects of the peptide on the whole heart under constant perfusion pressure and heart rate without the influence of either circulating humoral factors or other factors such as respiration and autonomic reflexes.
Materials and Methods Animals
Male Syrian CMHs (BIO 14.6; 300-330 days old) from the Canadian Hybrid Farm, Halls Harbour, Nova Scotia, Canada, and random-bred NHs of the same age were used. All were fed a regular diet of Purina Rodent Laboratory Chow 5001 (ICN Biochemicals, Cleveland, Ohio), which contains 23.4% protein, 4.5% fat, 4.25 kcal/g gross energy, 3.0 mg/g sodium, 11 .0 mg/g potassium, 12 .0 mg/g calcium, 2.1 mg/g magnesium, 5.8 mg/g chlorine, and 8.6 mg/g phosphorus, with ad lib intake of water in a climatecontrolled room for at least 1 week before the experiment. The animals were killed by excision of the heart under pentobarbital anesthesia as explained below. Baseline cardiac function was assessed in 49 CMHs and 39 NHs. Of these, 29 hamsters were used to test cardiac responses to angiotensins, comprising 15 CMHs and 14 NHs. Each category included two subgroups, one to test the dose-response curve to Ang I peptide (seven CMHs and seven NHs) and the other to test the doseresponse curve to Ang II peptide (eight CMHs and seven NHs). In addition, 10 hamsters were used to assess cardiac angiotensin receptor density and sensitivity (six CMHs and four NHs), and six others (three CMHs and three NHs) were used to assess the effect of blockade of Ang II 
Langendorff Preparation
The Langendorff preparation used in our laboratory has been described in detail previously. ' Immediately after the start of perfusion, the base of the pulmonary artery was incised to allow efficient drainage of the fluid accumulating from the coronary sinus and Thebesian vessels into the right ventricle. The time at which regular spontaneous beating of the heart resumed (usually below 10 seconds after starting perfusion) was noted as time zero of the experiment. Five minutes after the beginning of the spontaneous heart beating, a tipped-transducer catheter (Millar Instrument) was inserted gently into the LV via the mitral valve. The atrioventricular node was then crushed by small forceps, and the heart was immediately paced at a constant rate of 240 beats/ min to avoid the effects of different or varying heart rate on indexes of cardiac performance.20 Pacing was achieved by a stimulator (Model S-9, Grass Instruments, Quincy, Massachusetts); the duration of the stimulus was 5 msec at 2-3 V.
Twenty-five to 30 minutes was allowed for equilibration. Data obtained included LV systolic and diastolic pressure and its first derivative, LV +dP/dt, monitored continuously and recorded on a Brush recorder (Gould, Cleveland, Ohio) at a paper speed of 0.05 mm/sec. At the end of the equilibration period, the paper speed was increased to 50 mm/sec to obtain baseline readings. Myocardial flow was measured by collecting the effluent for 5-minute periods. Myocardial flow rate was calculated in milliliters per gram of left ventricular weight per minute.
At the end of the experiment, heart, brain, and liver weights were obtained with a precision balance (model PC440, Mettler Instrument, Hightstown, New Jersey). LV weight was normalized both by body weight and by brain weight, since brain weight was reported to be constant irrespective of physiological or nutritional stimuli. 21 In some cases, liver, lung, and kidney were examined histologically after fixation with buffered formalin for evidence of congestion, and the LV specimen was examined for histological evidence of myocardial disease.
Protocol of the Study
Angiotensin dose-LV performance response curve was obtained for Ang I and II in cardiomyopathic and control hearts. The effects of Ang I and Ang II were coimpared. In all experiments, captopril (150 ,ug/ml)l4 was dissolved in the perfusate to block the intracardiac captopril-sensitive converting enzyme. Since Ang I and II may enhance the release of catecholamines from the nerve endings,22,23 all experiments were carried out in the presence of /3-blockade (100 nM propranolol in the perfusate)24; this dose of propranolol was found to completely block the maximum inotropic effect of isoproterenol (6.9 x10-2 yg/min) in the mammalian heart. Ang I and Ang II were prepared by M. Khosla, myocardial flow rate (in nanomoles per milliliter) or LV weight (in nanomoles per minute per gram LV). The LV pressure data were recorded continuously at a slow paper speed (0.05 mm/sec) throughout the study, but at the end of each infusion period, the paper speed was increased to 50 mm/sec to minimize reading errors. The myocardial flow was collected throughout each infusion period (5 minutes) and then normalized by LV weight as milliliters per gram of left ventricular weight per minute.
Assessment ofAng I and Ang II in the Effluent
Ang I and Ang II were labeled with 125J by the lactoperoxidase method, and the monoiodinated products were purified by reverse-phase highperformance liquid chromatography (HPLC) according to the method of Urata et al. 25 The specific activity of each iodinated angiotensin was 2,200 Ci/ mmol. To determine Ang I conversion to Ang II in the hamster heart, 2.5 pmol of [1I]Ang I was injected into the coronary artery of the hamster heart prepared in a Langendorff apparatus as described above. Twenty-five milliliters of the effluent from the hamster heart was collected into 100 ml ice-cold ethanol, well-vortexed, and evaporated to dryness by a stream of nitrogen gas. The resulting residue was resuspended into 200 ,l of 25 mM triethylammonium phosphate buffer (TEAP), pH Tachyphylaxis to repeated administration of Ang I was tested by repeated infusion of Ang I peptide in the same six graded infusion rates and doses as above, each for 5 minutes in two NH hearts. After completion of the first dose-response curve, Ang I infusion was discontinued, and recovery time was allowed to wash out Ang I, as denoted by restabilization of LV pressure. Ang I was infused again in the same graded doses in the same hamster heart. Statistical Analysis
All statistical analyses were done by PROPHET, a national computer resource supported in part by Biotechnology Resource Program, Division of Research Resources, National Institutes of Health. Comparison between the groups was evaluated by BMDP2V (analysis of variance and covariance including repeated measures). A two-way analysis of variance for repeated measures was used to compare different groups and the responses to different doses of Ang I or Ang II. If the interaction was significant, unpaired t test (for two groups) or one-way analysis of variance (for more than two groups) followed by Newman-Keuls multiple-range test was done. The changes in the parameters in each group were analyzed by one-way analysis of variance followed by Newman-Keuls multiple range test.26 Results 
Baseline Data
Basal characteristics of the hamsters were analyzed in 49 CMHs and 39 NHs including those 29 used for the Langendorff study. Body weight, brain weight, and liver weight were significantly smaller in of six unstable hearts were not included in this report, one CMH heart and one NH heart in the Ang I experiments and two CMH hearts and two NH hearts in the Ang II experiments. At all doses of Ang I (in the presence of 150 ,ug/ml captopril and 100 nM propranolol in the perfusate), LV developed pressure and LV +dP/dt were significantly lower (p<0.05) in CMH hearts (n=7) compared with NH hearts (n =7), as illustrated in Figure  3 . However, the increase in both LV pressure and LV +dP/dt from corresponding baseline values was significantly greater (approximately threefold) in CMH compared with NH hearts (Figure 4, top panel) . The peak increase in LV pressure in response to Ang I was 30±5 mm Hg in CMH hearts and 11±4 mm Hg in NH hearts (p<O.O1), while the peak rise in LV +dP/dt was 348±45 mm/sec in CMH hearts and 99±37 mm Hg/sec in NH hearts (p<O.O1).
Myocardial flow rate tended to decrease in both CMH and NH hearts during Ang I infusion ( Figure 4 , bottom panel); however, these changes did not attain statistical significance in CMH hearts but were significant in NH hearts.
LV pressure and LV +dP/dt responses to graded Ang II infusion were obtained in eight CMH hearts and seven NH hearts. These cardiac function indexes The observation that the positive inotropic effect of Ang I, and to a lesser extent Ang II, was accentuated in the CMH heart raises many questions about the physiological differences between the normal and diseased heart. One possible explanation of the accentuated response is an increased conversion of Ang I to Ang II in the CMH heart. This possibility is partly supported by the similar potency of Ang I and Ang II on the inotropic responses of CMH hearts compared with the lower potency of Ang I versus Ang II in NH hearts.
In conclusion, the present study demonstrates that the positive inotropic response to Ang I occurred in both CMH and NH hearts despite the presence of captopril in the perfusion medium and that the positive inotropic effect of Ang I was accentuated in the CMH compared with the NH heart. Although the mechanisms mediating these effects are still not clear, one may postulate that the concomitant reduction in myocardial flow rate and increased ventricular contractility favors a direct inotropic effect of angiotensins and suggests a differential in sensitivity to angiotensins between coronary vessels and myocardium in both NH and CMH hearts. The positive inotropic effect of Ang I in the presence of captopril, the absence of saturable Ang I binding sites, and the blockade of cardiac inotropic effect of Ang I (plus captopril) by [Sar',Thr8]Ang II may denote that Ang II has been generated and acted on Ang II receptors and that this conversion of Ang I to Ang II has been mediated via an alternate enzyme other than the captopril-sensitive one. Also, the lack of [1251]Ang II in the cardiac effluent after infusion of [1251]Ang I suggests tissue rather than luminal conversion of Ang I to Ang II or even an intermediate active peptide (other than Ang II) that will still act via Ang II receptors. Therefore, we suggest that, similar to exogenously administered Ang I, endogenously accumulated Ang I (during treatment of chronic heart failure with ACE inhibitors) might be converted in the heart to Ang II (or a fragment thereof), which will increase cardiac performance by direct effect on myocyte Ang II receptors. This chain of events might represent another mechanism by which ACE inhibitors mediate sustained control of congestive heart failure.
